Search Results

You are looking at 61 - 70 of 93 items for :

  • "dose intensity" x
Clear All
Full access

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler

Selectivity) study [abstract] . Blood 2008 ; 112 : Abstract 335 . 61 Hughes TP Branford S White DL . Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial

Full access

Michael D. Stubblefield, Harold J. Burstein, Allen W. Burton, Christian M. Custodio, Gary E. Deng, Maria Ho, Larry Junck, G. Stephen Morris, Judith A. Paice, Sudhakar Tummala and Jamie H. Von Roenn

multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer . J Clin Oncol 2000 ; 18 : 136 – 147 . 19 Maindrault-Goebel F de Gramont A Louvet C . High-dose

Full access

Ludmila Katherine Martin and Tanios Bekaii-Saab

in long-term clinical outcomes (such as disease-free and overall survivals) with prolonged follow-up from phase III trials, its integration into standard neoadjuvant CRT should then be considered. However, maintaining dose intensity may prove

Full access

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Joachim Baehring, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Matthias Holdhoff, Larry Junck, Thomas Kaley, Ronald Lawson, Jay S. Loeffler, Mary P. Lovely, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Ian Parney, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Stephanie Weiss, Patrick Yung Wen, Nicole McMillian and Anita M. Engh

high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma . Int J Radiat Oncol Biol Phys 2014 ; 88 : 793 - 800 . 61. Ney DE Carlson JA Damek DM . Phase II trial of

Full access

Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf

from supportive care or supportive therapies , which are prescribed to treat the side effects of disease-specific treatment or to allow for higher doses or dose intensities of the treatment to be delivered. A common understanding of the services

Full access

Boglarka Gyurkocza and Frederick R. Appelbaum

: the role of dose intensity . Leukemia 2006 ; 32 : 322 – 328 . 18. McClune B Weisdorf DJ DiPersio JF . Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and

Full access

Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon

prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy . J Korean Med Sci 2003 ; 18 : 849 – 854 . 114 Leaw

Full access

Adrienne G. Waks and Ann H. Partridge

(intravenous vs oral), schedules, and durations, and although it is clear that greater cumulative dose confers an increased risk of CRA, the impact of administration route and dose intensity/duration on CRA is not known. 14 Although some data suggest that

Full access

Peter F. Coccia, Alberto S. Pappo, Jessica Altman, Smita Bhatia, Scott C. Borinstein, Joseph Flynn, A. Lindsay Frazier, Suzanne George, Robert Goldsby, Robert Hayashi, Mary S. Huang, Rebecca H. Johnson, Lynda Kwon Beaupin, Michael P. Link, Kevin C. Oeffinger, Kathleen M. Orr, Damon Reed, Holly L. Spraker, Deborah A. Thomas, Margaret von Mehren, Daniel S. Wechsler, Kimberly F. Whelan, Brad Zebrack, Dorothy A. Shead and Hema Sundar

major consequence of cancer and its treatment in both men and women. 6 , 7 The impact of cancer treatment on fertility is related to patient age at the time of diagnosis and the treatment, and is dependent on the type, duration, and dose intensity of

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

representative of the general older population, because they were probably healthier than most older patients. Many of the treatment regimens used in these trials had lower dose-intensity than those in current use. Nevertheless, these studies are important